Pharmaceuticals, Biotechnology and Life Sciences
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.
The safety profile of KEYTRUDA was consistent with thatpreviously observed in gastric cancer
many patients with advancedrenal cell carcinoma need additional treatment options that can helpimprove survival outcomes
First Presentation of Overall Survival Data from Post-Hoc Analysis of KEYNOTE-189 in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer…
KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a…
Torque will test its Deep IL-15 Primed T Cells (TRQ-1501) with Merck, both as a single agent and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 1/2 study in multiple solid tumor indications.
Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.
OncoSec Medical Incorporated and GOG Foundation will jointly work to conduct a registration-enabled study of Tavo (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150), it was announced on Monday.
The US Food and Drug Administration approved Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic cervical cancer with disease…